Cross-comparison of cancer drug approvals at three international regulatory agencies

Background The primary objective of the present study was to examine the drug approval process and the time to approval (TTA) for cancer drugs by 3 major international regulatory bodies-Health Canada, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA)-and to explore differences in the drug approval processes that might contribute to any disparities. Methods The publicly available Health Canada Drug Product Database was surveyed for all marketed antineoplastic agents approved between 1 January 2005 and 1 June 2013. For the resulting set of cancer drugs, public records of sponsor submission and approval dates by Health Canada, the FDA, and the EMA were obtained. Results Overall, the TTA for the 37 antineoplastic agents that met the study criteria was significantly less for the FDA than for the EMA ((X) over bar = 6.7 months, p < 0.001) or for Health Canada (<(X)over bar> = 6.4 months, p < 0.001). The TTA was not significantly different for Health Canada and the EMA <(X)over bar> = 0.65 months, p = 0.89). An analysis of the review processes demonstrated that the primary reason for the identified discrepancies in TTA was the disparate use of accelerated approval mechanisms. Summary In the present study, we systematically compared cancer drug approvals at 3 international regulatory bodies. The differences in TTA reflect several important considerations in the regulatory framework of cancer drug approvals. Those findings warrant an enhanced dialogue between clinicians and government agencies to understand opportunities and challenges in the current approval processes and to work toward balancing drug safety with timely access.